Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan
In Vivo. 2020 May-Jun;34(3):1451-1457. doi: 10.21873/invivo.11928.
BACKGROUND/AIM: The aim of this study was to compare the tolerability and efficacy of bevacizumab monotherapy between older and younger patients with recurrent ovarian cancer.
We enrolled 32 patients with recurrent ovarian cancer who were treated with bevacizumab monotherapy and divided them into those who were 65 years and older (n=12) and those younger than 65 years (n=20).
Except for grade ≥3 proteinuria, incidences of adverse events did not differ significantly between the groups. Although older patients exhibited more frequently cycle delay caused by non-hematological toxicities, this difference was not significant. There was no significant difference in tumor response and survival between the groups.
Bevacizumab monotherapy was tolerable and effective for older patients with recurrent ovarian cancer compared with younger patients.
背景/目的：本研究旨在比较贝伐珠单抗单药治疗在老年和年轻复发性卵巢癌患者中的耐受性和疗效。
我们纳入了 32 例接受贝伐珠单抗单药治疗的复发性卵巢癌患者，并将其分为 65 岁及以上（n=12）和<65 岁（n=20）两组。
除了≥3 级蛋白尿外，两组不良事件的发生率无显著差异。虽然老年患者因非血液学毒性导致的周期延迟更为常见，但差异无统计学意义。两组的肿瘤反应和生存无显著差异。
与年轻患者相比，贝伐珠单抗单药治疗对老年复发性卵巢癌患者是安全有效的。
